Pipeline Watch: Phase III Readouts For Bimekizumab, RHB-104
Approvals For Lasmiditan In US, Perampanel In China
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
